Subjects with pre-existing cardiovascular symptoms who were receiving subitramine, an appetite suppressant, were found to be at increased risk of cardiovascular events while taking the drug. The study included 9806 overweight or obese subjects with pre-existing cardiovascular disease and/or type 2 diabetes. The subjects were randomly assigned to subitramine (4910 subjects) or a placebo (4896 subjects) in a double-blind fashion. The primary outcome measured was the occurrence of any of the following events: nonfatal myocardial infarction or stroke, resuscitation after cardiac arrest, or cardiovascular death. The primary outcome was observed in 560 subjects in the subitramine group and 492 subjects in the placebo group. Do the data give good reason to think that there is a difference between the proportions of treatment and placebo subjects who experienced the primary outcome? (Note that sibutramine has not been available in the United States since the end of 2010 due to its manufacturer's concerns over increased risk of heart attack or stroke, although at the present time it can still be purchased in other countries.)